公开(公告)号：US20170065188A1

公开(公告)日：2017-03-09

申请号：US15354623

申请日：2016-11-17

Applicant: Thomas Jefferson University

Inventor： Apurva JAIN ,  Jeffrey I. JOSEPH ,  Nance DICCIANI ,  Denise DEVINE ,  David DEMMER

IPC: A61B5/0205 ,  A61B5/00

CPC classification number: A61B5/02055 ,  A61B5/0006 ,  A61B5/0031 ,  A61B5/0215 ,  A61B5/02416 ,  A61B5/0816 ,  A61B5/14542 ,  A61B5/14551 ,  A61B5/686 ,  A61B5/6876 ,  A61B5/6879 ,  A61B2562/0247 ,  A61B2562/0271 ,  A61B2562/063

Abstract: An implantable vital sign sensor including a housing including a first portion, the first portion defining a first open end, a second open end opposite the first end, and a lumen there through, the first portion being sized to be implanted substantially entirely within the blood vessel wall of the patient. A sensor module configured to measure a blood vessel blood pressure waveform is included, the sensor module having a proximal portion and a distal portion, the distal portion being insertable within the lumen and the proximal portion extending outward from the first open end.

公开(公告)号：US20170056430A1

公开(公告)日：2017-03-02

申请号：US15095877

申请日：2016-04-11

Applicant: Thomas Jefferson University

Inventor： David W. Andrews ,  Douglas C. Hooper

IPC: A61K31/713 ,  C12N15/113 ,  A61K45/06

CPC classification number: A61K31/713 ,  A61K31/7125 ,  A61K45/06 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/315

Abstract: The present disclosure provides pharmaceutical compositions comprising nucleic acids capable of targeting IGF-1R expression in M2 cells. The present disclosure also provides methods for the selective reduction of M2 cells by targeting expression of IGF-1R in these cells. The present disclosure further provides methods for treating cancer and enhancing therapeutic by targeting expression of IGF-1R in M2 cells in patients. The pharmaceutical composition of the present invention is effective when administered systemically to subjects in need thereof. The ease of administration of the pharmaceutical composition facilitates treatment and enhances patient compliance.

Abstract translation: 本公开提供了包含能够靶向M2细胞中的IGF-1R表达的核酸的药物组合物。 本公开还提供了通过靶向IGF-1R在这些细胞中的表达来选择性还原M2细胞的方法。 本公开进一步提供了通过靶向患者的M2细胞中IGF-1R的表达来治疗癌症并增强治疗性的方法。 当对有需要的受试者全身施用时，本发明的药物组合物是有效的。 药物组合物的易于施用便于治疗并增强患者依从性。

公开(公告)号：US20160303107A1

公开(公告)日：2016-10-20

申请号：US15103234

申请日：2014-12-09

Applicant: THOMAS JEFFERSON UNIVERSITY

Inventor： Davide TROTTI ,  Piera PASINELLI ,  Michael R. JABLONSKI

IPC: A61K31/473 ,  A61K31/428

CPC classification number: A61K31/473 ,  A61K31/428 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/55 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention provides a method of treating or ameliorating a neurodegenerative disease in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a neurodegenerative disease drug, wherein the drug is a substrate of an ABC transporter inhibitor, wherein the mammal is further administered a therapeutically effective amount of an ABC transporter inhibitor, whereby the neurodegenerative disease is treated in the mammal. In certain embodiments, the neurodegenerative disease comprises at least one selected from the group consisting of spinal cord injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, prion disease, amyotrophic lateral sclerosis, a tauopathy, and chronic traumatic encephalopathy.

Abstract translation: 本发明提供了治疗或改善哺乳动物神经变性疾病的方法，所述方法包括向哺乳动物施用治疗有效量的神经变性疾病药物，其中所述药物是ABC转运蛋白抑制剂的底物，其中所述哺乳动物是 进一步施用治疗有效量的ABC转运蛋白抑制剂，由此在哺乳动物中治疗神经变性疾病。 在某些实施方案中，神经变性疾病包括选自脊髓损伤，阿尔茨海默氏病，帕金森氏病，亨廷顿病，朊病毒病，肌萎缩性侧索硬化，tau病变和慢性创伤性脑病中的至少一种。

公开(公告)号：US09429576B2

公开(公告)日：2016-08-30

申请号：US14520962

申请日：2014-10-22

Applicant: Thomas Jefferson University

Inventor： Scott A. Waldman ,  Jason Park ,  Stephanie Schulz

IPC: A61K39/395 ,  A61K9/127 ,  G01N33/574 ,  A61K31/7034 ,  A61K31/7048 ,  C12Q1/68 ,  A61K47/48 ,  A61K51/10 ,  C07K16/40

CPC classification number: A61K39/0011 ,  A61K9/127 ,  A61K31/7034 ,  A61K31/7048 ,  A61K47/6871 ,  A61K51/1075 ,  C07K16/3046 ,  C07K16/40 ,  C12N15/113 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/57419 ,  G01N33/57446 ,  G01N2333/988

Abstract: Screening and diagnostic reagents, kits and methods for primary and or metastatic stomach or esophageal cancer are disclosed. Compositions for and methods of imaging and treating primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing primary and/or metastatic stomach for esophageal cancer are disclosed.

Abstract translation: 公开了用于初级和/或转移性胃或食管癌的筛选和诊断试剂，试剂盒和方法。 公开了成像和治疗原发性和/或转移性胃或食管癌的组合物和方法。 公开了用于治疗和预防食管癌原发性和/或转移性胃的疫苗组合物和方法。

公开(公告)号：US20160152711A1

公开(公告)日：2016-06-02

申请号：US14528924

申请日：2014-10-30

Applicant: CITY OF HOPE ,  THOMAS JEFFERSON UNIVERSITY

Inventor： John C. WILLIAMS ,  Ulrich RODECK ,  Joshua M. DONALDSON ,  Csaba KARI

IPC: C07K16/28 ,  C07K16/32

CPC classification number: C07K16/2863 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/33 ,  C07K2319/50

Abstract: In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a cross-masked mAb heterodimer complex is provided, comprising a first masked mAb, comprising a first signal sequence, a first masking epitope sequence, a first linker that is cleavable by a protease specific to a target tissue, and a first antibody or fragment thereof; and a second masked mAb, comprising a second signal sequence, a second masking epitope sequence, a second linker that is cleavable by a protease specific to a target tissue, and a second antibody or fragment thereof.

Abstract translation: 在一个实施方案中，提供了掩蔽的单克隆抗体（mAb），由核酸序列或包含信号序列，掩蔽表位序列的氨基酸序列分子编码的mAb，可通过蛋白酶特异性的蛋白酶切割的接头序列 目标组织; 和抗体或其功能片段。 在另一个实施方案中，提供了跨屏蔽的mAb异二聚体复合物，其包含第一掩蔽的mAb，其包含第一信号序列，第一掩蔽表位序列，可被靶组织特异性的蛋白酶切割的第一接头， 抗体或其片段; 和第二掩蔽的mAb，其包含第二信号序列，第二掩蔽表位序列，可被靶组织特异性的蛋白酶切割的第二接头和第二抗体或其片段。

公开(公告)号：US20160074389A1

公开(公告)日：2016-03-17

申请号：US14785553

申请日：2014-04-18

Applicant: THOMAS JEFFERSON UNIVERSITY

Inventor： Michael P. LISANTI

IPC: A61K31/495 ,  G01N33/574 ,  C12Q1/68

CPC classification number: A61K31/495 ,  A61N5/10 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N2333/705

Abstract: This invention provides a method for treating a subject afflicted with glioblastoma multiforme comprising administering a therapeutically effective regimen of temoxolomide to be glioblastoma multiforme-afflicted subject, wherein the subject's glioblastoma multiforme cells are known to be caveolin-1-positive. This invention also provides a method for determining whether a subject afflicted with glioblastoma multiforme is likely to progress therapeutically in response to a therapeutically effective regimen of temoxolomide comprising determining whether the subject's glioblastoma multiforme cells are caveolin-1-positive, whereby if the subject's glioblastoma multiforme cells are caveolin-1-positive, the subject is likely to progress therapeutically in response to a therapeutically effective regimen of temozolomide.

Abstract translation: 本发明提供了治疗患有多形性成胶质细胞瘤的受试者的方法，其包括将治疗有效的方法的替莫唑胺作为多形性成胶质细胞瘤受试者，其中已知受试者的多形性成胶质细胞瘤多形性细胞是窖1阳性的。 本发明还提供了一种用于确定受多形性成胶质细胞瘤影响的受试者是否可能响应于治疗有效的替莫唑胺方案进行治疗的方法，包括确定受试者的多形性成胶质细胞瘤多形性细胞是否是窖1阳性，如果受试者的多形性成胶质细胞瘤 细胞是窖1阳性，受试者可能响应于替莫唑胺的治疗有效方案而进行治疗。

公开(公告)号：US20160000808A1

公开(公告)日：2016-01-07

申请号：US14794416

申请日：2015-07-08

Applicant: UNIVERSITY OF MARYLAND ,  UNIVERSITY OF MARYLAND EASTERN SHORE ,  THOMAS JEFFERSON UNIVERSITY

Inventor： Vincent C.O. Njar ,  Lalji K. Gediya ,  Puranik Purushottamachar ,  Abhijit Godbole ,  Andrew Kwegyir-Afful ,  Tadas Vasaitis

IPC: A61K31/58 ,  A61N5/10 ,  A61K45/06

CPC classification number: A61K31/58 ,  A61K45/06 ,  A61N5/10 ,  C07J43/003 ,  A61K2300/00

Abstract: The present disclosure provides the design and synthesis of novel steroidal compounds that cause down-regulation of the androgen receptor (AR), both full length and splice variant. The compounds are potential agents for the treatment of all forms of prostate cancer and other diseases that depend on functional AR.

公开(公告)号：US20150368647A1

公开(公告)日：2015-12-24

申请号：US14846193

申请日：2015-09-04

Applicant: THOMAS JEFFERSON UNIVERSITY

Inventor： Carlo M. Croce ,  Chang-Gong Liu ,  George A. Calin ,  Cinzia Sevignani

IPC: C12N15/113

CPC classification number: C12N15/1135 ,  A61K31/7088 ,  A61K31/713 ,  A61K45/06 ,  C12N7/00 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/141 ,  C12N2310/31 ,  C12N2310/32 ,  C12N2310/33 ,  C12N2710/16143 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/178

Abstract: MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers.

Abstract translation: MicroRNA基因与涉及不同癌症病因的染色体特征高度相关。 由这些与癌症相关的染色体特征引起的细胞的基因组结构或染色体结构的扰动可影响位于该染色体特征附近的miR基因的表达。 因此，miR基因表达的评估可用于指示受试者中存在致癌染色体损伤。 由于由癌相关的染色体特征引起的miR基因表达水平的变化也可能导致致癌作用，可以通过将miR基因表达水平恢复到正常来治疗给定的癌症。 microRNA表达谱可用于诊断癌症并预测特定癌症是否与不良预后相关。 与CLL患者中含有miR基因的基因组区域相关的特异性突变的鉴定提供了诊断CLL和可能的其他癌症的手段。

公开(公告)号：US20150368350A1

公开(公告)日：2015-12-24

申请号：US14763730

申请日：2014-01-31

Applicant: THOMAS JEFFERSON UNIVERSITY

Inventor： Mark L. Tykocinski ,  Matthew Charles Weber

IPC: C07K16/28 ,  A61K39/395 ,  C07K14/705

CPC classification number: C07K16/2878 ,  A61K39/3955 ,  C07K14/70575 ,  C07K2317/622 ,  C07K2317/75 ,  C07K2319/00

Abstract: Members of the TNF ligand/TNF receptor superfamily play key roles in a large number of biological events. For instance, members of the TNF ligand/TNF receptor superfamily figure prominently in the complex interplay of positive and negative signals that regulate T cell activation, maintenance of T cell effector function, promotion of maturation of antigen-presenting cells, such as dendritic cells, and the T cell stimulation of APCs. TNF receptors are broadly classified in three groups Receptors in the first group contain a death domain in their cytoplasmic tails. Receptors in the second group contain a TRAF interaction motif in their cytoplasmic tails. The third group of TNF receptors do not contain functional intracellular signaling domains but can act as decoy receptors.

Abstract translation: TNF配体/ TNF受体超家族的成员在大量生物事件中起关键作用。 例如，TNF配体/ TNF受体超家族的成员在调节T细胞活化，维持T细胞效应子功能，促进抗原呈递细胞如树突状细胞成熟的正和负信号的复杂相互作用中显着地排列， 和APC的T细胞刺激。 TNF受体大致分为三组。第一组的受体在其细胞质尾部含有死亡结构域。 第二组的受体在其细胞质尾部含有TRAF相互作用基序。 第三组TNF受体不含功能性细胞内信号结构域，但可以作为诱饵受体。

公开(公告)号：US09150859B2

公开(公告)日：2015-10-06

申请号：US14281756

申请日：2014-05-19

Applicant: Thomas Jefferson University

Inventor： Carlo M. Croce ,  Chang-Gong Liu ,  George A. Calin ,  Cinzia Sevignani

IPC: C07H21/02 ,  C07H21/04 ,  A61K48/00 ,  C12N15/113 ,  C12Q1/68 ,  A61K31/7088 ,  A61K31/713 ,  A61K45/06

CPC classification number: C12N15/1135 ,  A61K31/7088 ,  A61K31/713 ,  A61K45/06 ,  C12N7/00 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/141 ,  C12N2310/31 ,  C12N2310/32 ,  C12N2310/33 ,  C12N2710/16143 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/178

Abstract: MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers.

Abstract translation: MicroRNA基因与涉及不同癌症病因的染色体特征高度相关。 由这些与癌症相关的染色体特征引起的细胞的基因组结构或染色体结构的扰动可影响位于该染色体特征附近的miR基因的表达。 因此，miR基因表达的评估可用于指示受试者中存在致癌染色体损伤。 由于由癌相关的染色体特征引起的miR基因表达水平的变化也可能导致致癌作用，可以通过将miR基因表达水平恢复到正常来治疗给定的癌症。 microRNA表达谱可用于诊断癌症并预测特定癌症是否与不良预后相关。 与CLL患者中含有miR基因的基因组区域相关的特异性突变的鉴定提供了诊断CLL和可能的其他癌症的手段。